Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E13.14 EPS (ttm)5.40 Insider Own0.20% Shs Outstand1.31B Perf Week0.81%
Market Cap92.65B Forward P/E10.42 EPS next Y6.81 Insider Trans-10.30% Shs Float1.28B Perf Month-2.56%
Income7.07B PEG- EPS next Q1.71 Inst Own81.80% Short Float1.09% Perf Quarter-5.24%
Sales22.28B P/S4.16 EPS this Y-22.80% Inst Trans0.39% Short Ratio2.09 Perf Half Y4.99%
Book/sh17.64 P/B4.02 EPS next Y-1.79% ROA2.40% Target Price86.15 Perf Year-2.65%
Cash/sh21.79 P/C3.25 EPS next 5Y-5.04% ROE7.40% 52W Range64.27 - 89.54 Perf YTD-1.01%
Dividend2.28 P/FCF18.55 EPS past 5Y36.20% ROI19.90% 52W High-20.80% Beta1.03
Dividend %3.21% Quick Ratio3.40 Sales past 5Y21.90% Gross Margin79.60% 52W Low10.35% ATR2.09
Employees10000 Current Ratio3.50 Sales Q/Q-14.10% Oper. Margin42.00% RSI (14)48.02 Volatility2.38% 3.23%
OptionableYes Debt/Eq1.19 EPS Q/Q-22.10% Profit Margin7.10% Rel Volume0.66 Prev Close70.49
ShortableYes LT Debt/Eq1.07 EarningsOct 25 AMC Payout180.20% Avg Volume6.68M Price70.92
Recom2.20 SMA20-0.57% SMA50-3.44% SMA200-4.67% Volume4,431,523 Change0.61%
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Nov-13-18 07:00AM  Express Scripts offers new formulary for lower list-price drugs Reuters
Nov-12-18 05:01PM  Gilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27 Business Wire
Nov-10-18 09:54AM  Biotech stocks have been hit hard here are ones analysts like best for a rebound MarketWatch
Nov-09-18 08:00AM  Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018 Business Wire
08:00AM  Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018 Business Wire
08:00AM  Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018 Business Wire
07:27AM  Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels MarketWatch
Nov-08-18 12:57PM  Is Gilead Sciences Incs (NASDAQ:GILD) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
09:57AM  East Bay biotech scores $42 million with potential quick-fix for heart trouble American City Business Journals
Nov-05-18 08:23PM  Exclusive: Small Peninsula city urges developer to go bigger on new housing site American City Business Journals
10:27AM  Why Gilead Sciences, Inc. Stock Broke Down in October Motley Fool
Nov-03-18 04:52PM  3 Top Biotech Stocks With P/Es Below 14 Motley Fool
Nov-02-18 02:55PM  Gilead Stock to Jump Double Digits: Morgan Stanley Investopedia
01:47PM  Gilead Sciences Is Sporting a Bearish Set of Charts for Investors TheStreet.com
10:17AM  bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat Zacks
03:45AM  Decatur-based task force becoming ground zero for global elimination of hepatitis B and C American City Business Journals
Nov-01-18 03:34PM  Biotech ETFs in Focus on String of Q3 Earnings Beat Zacks
09:00AM  Gilead to Present Latest Scientific Research in Hematologic Malignancies and Solid Tumors at ASH 2018 Business Wire
08:23AM  3 Big Stock Charts for Thursday: Walmart, Prologis and Incyte InvestorPlace
08:00AM  Today's Research Reports on Trending Tickers: Gilead Sciences and BeiGene ACCESSWIRE
07:42AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals Zacks
Oct-31-18 05:48PM  Jerome Dodson Comments on Gilead Sciences GuruFocus.com -5.36%
12:51PM  Gilead shares drop after new UnitedHealth program incentivizes cheaper HIV meds MarketWatch
08:30AM  Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies Business Wire
07:55AM  Investor Expectations to Drive Momentum within Gilead Sciences, SCANA, Brink's, Fortive, Asbury Automotive Group, and Helmerich & Payne Discovering Underlying Factors of Influence GlobeNewswire
07:00AM  Market Morning: Record Down Days, Biotech Buyback Busts, Coke Raising Prices, Credit Tightens Market Exclusive
Oct-30-18 06:36AM  Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy Business Wire
06:33AM  Better Buy: Celgene Corporation vs. Gilead Sciences Motley Fool
Oct-29-18 10:04PM  Edited Transcript of GILD earnings conference call or presentation 25-Oct-18 8:30pm GMT Thomson Reuters StreetEvents
05:45PM  Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
04:53PM  Gilead charged $1,100 a day for this drug. Now it will launch a generic at quarter the price. American City Business Journals
01:44PM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2 Zacks
12:09PM  7 Rising Healthcare Stocks to Consider InvestorPlace
11:24AM  The bigger message behind Amgens decision to slash cost of its Repatha cholesterol drug MarketWatch
06:53AM  Be Ready to Ride the Dividend on Gilead Sciences TheStreet.com
05:48AM  The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers (Revised) Zacks
Oct-27-18 08:31AM  AbbVie Takes Aim at Vertex Pharmaceuticals Incorporated Motley Fool
07:00AM  Where Will Gilead Sciences, Inc. Be in 5 Years? Motley Fool
Oct-26-18 04:30PM  Gilead Sciences Stock Is Back to Base Go Long InvestorPlace
11:09AM  Gilead Sciences Stock Divides Analysts After Earnings Report Barrons.com
10:06AM  Gilead (GILD) Beats on Q3 Earnings & Sales, Updates View Zacks
09:05AM  [$$] Stocks to Watch: Amazon, Alphabet, Intel, Chipotle, Snap, Expedia The Wall Street Journal
08:17AM  The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default Benzinga
08:00AM  Today's Research Reports on Trending Tickers: Gilead Sciences, Inc. and Esperion Therapeutics, Inc. ACCESSWIRE
07:31AM  Gilead Sciences' 3rd Quarter: Good News Gets Better, Bad News Gets Worse Motley Fool
02:57AM  Gilead Sciences Inc (GILD) Q3 2018 Earnings Conference Call Transcript Motley Fool
Oct-25-18 06:15PM  Gilead hepatitis C drug sales fall, but profit beats estimates Reuters
05:56PM  UPDATE 1-Gilead hepatitis C drug sales fall, but profit beats estimates Reuters
05:56PM  Gilead 3rd quarter profit falls as hepatitis C drug sales wane Reuters
05:30PM  Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates Zacks
04:12PM  Gilead's stock gains on better-than-expected earnings MarketWatch
04:11PM  Gilead Beats Third-Quarter Sales, Adjusted Profit Views Investor's Business Daily
04:02PM  Gilead Sciences Announces Fourth Quarter 2018 Dividend Business Wire
04:01PM  Gilead Sciences Announces Third Quarter 2018 Financial Results Business Wire
03:20PM  Gilead Sciences beats earnings, revenues expectations CNBC Videos
11:39AM  Gilead earnings: Expect a strong quarter despite executive turnover MarketWatch
08:24AM  A Preview Of Gilead's Q3 Earnings Benzinga
Oct-24-18 04:52PM  3 Top Healthcare Stocks to Buy Right Now Motley Fool -5.11%
11:20AM  Healthcare ETFs to Buy Ahead of Q3 Earnings Zacks
10:54AM  Investors Are Underestimating Gilead Sciences Stock InvestorPlace
09:33AM  Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG Zacks
Oct-23-18 03:47PM  Why CASI Pharmaceuticals Inc. Is Rocketing Higher Today Motley Fool
11:09AM  Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook Zacks
07:36AM  The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers Zacks
Oct-22-18 05:36PM  Will Gilead (GILD) HIV Sales Offset HCV Sales Decline in Q3? Zacks
01:17PM  POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET GlobeNewswire
01:15PM  Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet Business Wire
Oct-20-18 06:32PM  PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS TO BE PRESENTED AT 2018 ACR/ARHP ANNUAL MEETING GlobeNewswire
06:30PM  Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting Business Wire
Oct-19-18 05:41PM  Jackpot stocks that could make you a billionaire CNBC Videos
03:15PM  Could a Diagnostic Be Key to Winning This Big Healthcare Market? Motley Fool
08:00AM  Investors Hunt for Biotech Winners as Wider Stock Market Churns Bloomberg
Oct-18-18 09:21PM  Can UnitedHealth Group and Johnson & Johnson Continue Their Winning Ways? Motley Fool
05:45PM  Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know Zacks
01:33PM  Risk-Reward With Gilead Sciences GuruFocus.com
07:00AM  Edited Transcript of GILD earnings conference call or presentation 25-Jul-18 9:00pm GMT Thomson Reuters StreetEvents
07:00AM  Market Morning: China, Yuan Crushed; Fed Minutes Sparse, HIV Meets Match, Exxon Wants China Market Exclusive
06:31AM  Is Sangamo Therapeutics Inc. a Buy? Motley Fool
Oct-16-18 03:01PM  Can This Tiny Biotech Revolutionize a $35 Billion Market? Motley Fool
10:00AM  Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock Motley Fool
Oct-15-18 06:04PM  Trump administration: Drug makers should disclose prices in TV ads Yahoo Finance
08:04AM  2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better Motley Fool
Oct-12-18 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
Oct-11-18 05:34PM  Why a Peninsula cancer fighter soared nearly 40% after record-breaking IPO American City Business Journals
04:05PM  Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018 Business Wire
03:23PM  Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018 Business Wire
Oct-10-18 10:23AM  Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates Zacks
10:18AM  Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status Zacks
Oct-09-18 04:35PM  Better Buy: Crispr Therapeutics AG vs. Editas Motley Fool
11:08AM  Estimating The Intrinsic Value Of Gilead Sciences Inc (NASDAQ:GILD) Simply Wall St.
Oct-05-18 06:14PM  Gilead Sciences (GILD) Stock Moves -0.24%: What You Should Know Zacks
09:55AM  Gilead Announces Positive Data From Ongoing Biktarvy Study Zacks
Oct-04-18 02:24PM  7 Healthcare Stocks to Buy Right Now InvestorPlace
09:19AM  Better Buy: Gilead Sciences, Inc. vs. Pfizer Motley Fool
Oct-03-18 07:33PM  Top 5 Biotech Stocks for 2018 Investopedia
05:30PM  Chartmaster says it's time to fade one of this year's bes... CNBC Videos
04:51PM  Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors Zacks
10:54AM  Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs Zacks
04:55AM  Hong Kong Department of Health Approves Biktarvy(R) (bictegravir, emtricitabine, tenofovir alafenamide) PR Newswire
04:34AM  Hong Kong Department of Health Approves Biktarvy(R) (bictegravir, emtricitabine, tenofovir alafenamide) PR Newswire
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; and AELIX Therapeutics S.L. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CDirectorNov 01Option Exercise23.6050,0001,180,0003,067,762Nov 05 07:45 PM
MARTIN JOHN CDirectorNov 01Sale69.5550,0003,477,6173,017,762Nov 05 07:45 PM
MARTIN JOHN CDirectorOct 01Option Exercise23.6050,0001,180,0003,067,762Oct 03 05:45 PM
MARTIN JOHN CDirectorOct 01Sale78.0450,0003,902,2103,017,762Oct 03 05:45 PM
MARTIN JOHN CDirectorSep 04Option Exercise23.6050,0001,180,0003,067,762Sep 06 05:24 PM
MARTIN JOHN CDirectorSep 04Sale74.1650,0003,708,0343,017,762Sep 06 05:24 PM
MARTIN JOHN CDirectorAug 01Option Exercise23.6050,0001,180,0003,067,762Aug 03 04:41 PM
MARTIN JOHN CDirectorAug 01Sale77.8550,0003,892,6503,017,762Aug 03 04:41 PM
MARTIN JOHN CDirectorJul 02Option Exercise23.6050,0001,180,0003,067,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJul 02Sale70.8150,0003,540,2823,017,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJun 01Option Exercise23.6050,0001,180,0003,067,762Jun 05 07:34 PM
MARTIN JOHN CDirectorJun 01Sale68.1350,0003,406,4953,017,762Jun 05 07:34 PM
Cogan John FrancisDirectorMay 04Option Exercise26.625,836155,32558,455May 08 01:59 PM
MILLIGAN JOHN FPresident and CEOMay 04Option Exercise27.0780,0002,165,6001,294,306May 08 06:29 PM
Cogan John FrancisDirectorMay 04Sale65.095,836379,88552,619May 08 01:59 PM
MARTIN JOHN CDirectorMay 01Option Exercise23.6050,0001,180,0003,067,762May 03 01:07 PM
MARTIN JOHN CDirectorMay 01Sale72.1950,0003,609,6603,017,762May 03 01:07 PM
Cogan John FrancisDirectorApr 27Option Exercise26.625,833155,24558,452Apr 30 05:39 PM
Cogan John FrancisDirectorApr 27Sale73.915,833431,11752,619Apr 30 05:39 PM
Cogan John FrancisDirectorApr 20Option Exercise26.625,833155,24558,452Apr 23 07:16 PM
Cogan John FrancisDirectorApr 20Sale73.745,833430,13052,619Apr 23 07:16 PM
Cogan John FrancisDirectorApr 13Option Exercise26.625,833155,24558,452Apr 16 06:45 PM
Cogan John FrancisDirectorApr 13Sale75.565,833440,74152,619Apr 16 06:45 PM
Cogan John FrancisDirectorApr 06Option Exercise26.625,833155,24558,452Apr 09 06:41 PM
Cogan John FrancisDirectorApr 06Sale74.475,833434,38452,619Apr 09 06:41 PM
Cogan John FrancisDirectorApr 02Option Exercise26.625,833155,24558,452Apr 04 04:23 PM
MARTIN JOHN CDirectorApr 02Option Exercise23.6050,0001,180,0003,067,762Apr 04 07:34 PM
MARTIN JOHN CDirectorApr 02Sale73.1450,0003,656,8063,017,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Sale74.935,833437,06752,619Apr 04 04:23 PM
Cogan John FrancisDirectorMar 23Option Exercise26.625,833155,24558,452Mar 26 06:48 PM
Cogan John FrancisDirectorMar 23Sale75.025,833437,58852,619Mar 26 06:48 PM
Cogan John FrancisDirectorMar 16Option Exercise26.625,833155,24558,452Mar 20 01:28 PM
Cogan John FrancisDirectorMar 16Sale80.095,833467,13852,619Mar 20 01:28 PM
Cogan John FrancisDirectorMar 12Option Exercise26.625,833155,24558,452Mar 13 04:29 PM
Cogan John FrancisDirectorMar 12Sale80.935,833472,06552,619Mar 13 04:29 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise23.6050,0001,180,0003,067,762Mar 05 06:54 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Option Exercise40.5617,250699,66069,426Mar 05 07:04 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00178012,233Mar 05 08:42 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Sale78.6925,0001,967,31544,426Mar 05 07:04 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale78.6550,0003,932,3753,017,762Mar 05 06:54 PM
Washington Robin LEVP, CFOFeb 28Sale80.315,000401,566105,405Mar 02 06:47 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 20Sale81.5414,4351,176,9920Feb 21 06:51 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.00908016,237Feb 13 04:58 PM
WILSON GAYLE EDirectorFeb 09Option Exercise26.6260,0001,596,900182,258Feb 13 05:24 PM
WILSON GAYLE EDirectorFeb 09Sale77.9260,0004,675,080122,258Feb 13 05:24 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise23.6050,0001,180,0003,046,766Feb 05 08:38 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Option Exercise40.5617,250699,66062,738Feb 05 09:20 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.00620015,547Feb 02 09:14 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Sale83.5125,0002,087,86037,738Feb 05 09:20 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale83.5650,0004,177,8242,996,766Feb 05 08:38 PM
Meyers James REVP Worldwide Commercial OpsJan 16Option Exercise21.58100,0002,157,500102,715Jan 18 06:31 PM
Meyers James REVP Worldwide Commercial OpsJan 16Sale80.24100,0008,024,3642,715Jan 18 06:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Option Exercise36.0225,875932,06275,488Jan 16 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Sale79.0030,0002,370,00045,488Jan 16 05:42 PM
MARTIN JOHN CExecutive ChairmanJan 02Option Exercise23.6050,0001,180,0003,046,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Option Exercise24.918,625214,80664,613Jan 04 08:05 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Sale73.8715,0001,108,01949,613Jan 04 08:05 PM
MARTIN JOHN CExecutive ChairmanJan 02Sale73.6250,0003,681,2352,996,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Option Exercise24.918,625214,80670,988Dec 05 06:17 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise21.5873,3331,582,1593,070,099Dec 05 07:49 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale74.9873,3335,498,3852,996,766Dec 05 07:49 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Sale74.6415,0001,119,55255,988Dec 05 06:17 PM